Browse the evidence

By the fifth month, nearly one-half (46%) of semaglutide users had discontinued the treatment.

Practitioners should be aware of the high discontinuation rates when prescribing semaglutide.

Higher discontinuation rates were associated with lower household income and education level.

Socioeconomic factors should be considered when evaluating patient adherence to semaglutide.

If clinicians elect to use compounded incretin‐based therapy, they must consider the potential harms and benefits for each patient.

Clinicians should evaluate individual patient needs and educate them on therapy administration.

Obesity is associated with comorbidities such as metabolic and cardiovascular diseases, orthopaedic and psychiatric conditions, and cancer.

Healthcare providers should be aware of the serious health risks associated with obesity.

Diet and exercise are not effective as sole management of severe obesity.

Clinicians should consider additional interventions beyond diet and exercise for severe obesity.

Therapy was stopped in 2 patients, both of whom had resolution of symptoms.

Stopping semaglutide may resolve allodynia symptoms in affected patients.

Two patients opted to continue semaglutide despite the adverse effect, with one experiencing resolution after 4 months.

Some patients may choose to continue semaglutide, and symptom resolution can occur over time.

Redemption was higher for females, Asian participants, and those reporting Spanish as their preferred language compared to their counterparts.

Demographic factors such as gender, ethnicity, and language preference may influence redemption rates in produce prescription programs.

Current anti-obesity drugs have limitations regarding efficacy, side effects, weight regain, and high costs.

Awareness of these limitations can guide practitioners in seeking innovative treatment options.

No significant further benefits of ingesting multi-ingredient supplements (MTN) compared to calorie equivalent comparator (COMP) supplements were identified for fat-free mass (FFM), upper-body strength, lower-body strength, and functional capacity.

Practitioners should consider that multi-ingredient supplements may not provide additional benefits over calorie equivalent supplements for body composition and performance in this population.

Obesity is a debilitating disease that requires refined, concept-driven therapeutic approaches.

Health professionals should adopt refined therapeutic approaches to address obesity.

The 'Behavioral Balance Model' integrates biological, psychological, social, economic, and environmental aspects of obesity.

Practitioners should consider a multifaceted approach to understanding and treating obesity.

Further studies are needed to investigate the safety and efficacy of glucagon and GLP-1 receptor co-agonists.

Practitioners should be aware that while glucagon and GLP-1 co-agonists show promise, more research is needed before widespread clinical application.

Cagrilintide, a stable amylin analogue, is under clinical development for obesity treatment.

Cagrilintide may offer a new approach to obesity management.

Nonshivering thermogenesis (NST) has potential for activating energy balance processes without significant side effects.

Practitioners may consider NST as a viable strategy for enhancing energy balance in obesity management.

There was no significant relative change in disability benefit receipt for the ILI group compared to controls.

Intensive lifestyle interventions may not affect disability benefit receipt despite improving employment.

The 7-year cardiovascular risk was 17.4% in the surgery group with preoperative preparation and 18.8% in the no-surgery group, with a risk difference of -1.4.

Preoperative preparation combined with bariatric surgery does not significantly reduce cardiovascular risk.

Strategic dietary modulation, particularly a marked reduction in LA intake, may restore mitochondrial redox homeostasis and improve metabolic health.

Reducing linoleic acid in the diet could enhance mitochondrial function and overall metabolic health.

Subgroup analyses showed no effect on results when stratifying studies according to combined SJ + MJ versus MJ training alone.

Combining SJ and MJ exercises does not show a distinct advantage in hypertrophy outcomes.

There was a 100-fold increase in the prescription period prevalence of weight loss agents in the active component from their initial authorization date.

Practitioners should be aware of the significant increase in weight loss medication prescriptions among military personnel.

Service members in health care occupations and the Navy had higher prevalence of weight loss medication prescriptions compared to other service branches and occupations.

This information can inform targeted strategies for weight loss medication distribution within the military.

The number of bariatric surgeries in Germany is significantly increasing.

Healthcare providers should be aware of the growing demand for bariatric surgery.

GLP-1ra users have similar postoperative outcomes following body contouring surgery compared to non-GLP-1ra controls.

Practitioners can consider GLP-1ra use as not adversely affecting postoperative outcomes in body contouring surgeries.

Postoperative cellulitis occurred less frequently among GLP-1ra users in matched cohorts.

GLP-1ra use may be associated with a lower risk of postoperative cellulitis.